Compare Cronos Group Inc (CRON) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs Enveric Biosciences Inc — how do they compare? Cronos Group Inc trades at $3.23 (market cap $1.18B), while Enveric Biosciences Inc trades at $1.48 (market cap $6.80M). The key difference: Cronos Group Inc is far larger — about 173.5× Enveric Biosciences Inc's market cap, and Cronos Group Inc is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cronos Group Inc for 22 Days and Enveric Biosciences Inc for 14 Days on average.
| CRON | ENVB | |
|---|---|---|
Market Cap | $1.18B | $6.80M |
Volume | 968,037 | 64,867 |
Sector | Health | Health |
52-Week High | $3.55 | $10.80 |
52-Week Low | $2.30 | $1.27 |
Typical Hold Time | 22 Days | 14 Days |
Enterprise Value | $387.62M | -$1.49M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.22, down 0.62% on the day, with a bearish technical signal and neutral oscillators. Revenue grew to $146.59M in 2025, but net income was -$9.45M. Recent Q2 2026 earnings beat expectations with EPS of $0.09. The company held its first Investor Day in September 2026, highlighting international expansion and cash flow focus.
Outlook is mixed: strong revenue growth and a solid balance sheet with no debt support upside, but profitability remains inconsistent. Risks include cash flow volatility and competitive pressures. Analyst consensus is cautious with 60% hold ratings, reflecting uncertainty amid expansion efforts.
ENVB trades at $1.45, down 3.01% on the day, with a bearish technical signal driven by moving averages. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten quarterly EPS expectations. Recent positive developments include a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in investor conferences.
The outlook is mixed; analyst consensus is 75% buy with strong earnings beats, but high negative ROE/ROA and operational cash burn pose significant risks. Investment opportunity hinges on successful drug development, while key risks include funding needs and clinical trial outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
